SCHEMBL17010367

SCHEMBL17010367

CC(=O)Oc1ccc(NC(=O)c2c(O)[nH]c(=O)[nH]c2=O)cc1C(=O)O

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
XDH P47989 17/20 0.57
SLC22A12 Q96S37 11/20 0.55
KDM4E B2RXH2 1/20 0.51
MEN1 O00255 1/20 0.51
USP2 O75604 1/20 0.51
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
HPGD P15428 1/20 0.51
CASP1 P29466 1/20 0.51
BRCA1 P38398 1/20 0.51
HTT P42858 1/20 0.51
CASP7 P55210 1/20 0.51
KMT2A Q03164 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17010221 0.82 XDH (0.67) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL17010326 0.81 XDH (0.66) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL17010257 0.81 XDH (0.66) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL10334083 0.75 CFD (0.63) KDM4EMEN1ALDH1A1LMNAHPGD
SCHEMBL17010317 0.74 XDH (0.70) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL17010244 0.74 XDH (0.77) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL20179459 0.73 XDH (1.00) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL16708623 0.73 XDH (0.78) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL16700088 0.72 XDH (1.00) XDHSLC22A12KDM4EMEN1USP2
SCHEMBL10926831 0.72 SLC22A12 (1.00) XDHSLC22A12KDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093631-B2 Bifunctional compounds and use for reducing uric acid levels ACQUIST LLC (US) 2018-10-09 US disclosed
US-20170197923-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels ACQUIST LLC 2017-07-13 US disclosed
EP-3104861-A1 BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS Warrell, Raymond P., Jr. (US) 2016-12-21 EP disclosed
WO-2015123003-A1 BIFUNCTIONAL COMPOUNDS AND USE FOR REDUCING URIC ACID LEVELS WARRELL RAYMOND P (US) 2015-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170197923-A1 Bifunctional Compounds and Use for Reducing Uric Acid Levels XDH, OAT, ATIC XDH 1/4885SLC22A12 264/4885KDM4E 4691/4885
US-10093631-B2 Bifunctional compounds and use for reducing uric acid levels XDH, OAT, ATIC XDH 1/4885SLC22A12 264/4885KDM4E 4691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.